Author： Taubert Helge Magdolen Viktor Kotzsch Matthias
Publisher： Future Medicine
ISSN： 1752-0363
Source： Biomarkers in Medicine, Vol.7, Iss.3, 2013-06, pp. : 473-480
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The uPA system mainly comprises the urokinase-type plasminogen activator uPA, the cell-surface receptor uPA receptor and the inhibitor PAI-1. Its clinical and prognostic impact especially in breast cancer is well investigated. In this short report, we summarize the published data describing expression of uPA, PAI-1 and uPA receptor and their relevance to clinical and survival data in sarcomas underlining their impact as tumor biomarkers in this tumor type as well.
Related content
Access to resources
Recommend
Primary Sarcomas of the Central Nervous System
Oncology, Vol. 58, Iss. 3, 2000-04 ,pp. :
By Kasperska-Zajac Alicja Rogala Barbara
Inflammation, Vol. 29, Iss. 2-3, 2005-06 ,pp. :
By Harbeck Nadia Schmitt Manfred Paepke Stefan Allgayer Heike Kates Ronald
Critical Reviews in Clinical Laboratory Sciences, Vol. 44, Iss. 2, 2007-03 ,pp. :